US global tariffs will rise to 15%, Donald Trump says

British manufacturers woke up this morning to a fresh headache: Donald Trump has raised his global tariff rate to 15%, superseding the 10% baseline announced just hours earlier after the Supreme Court dismantled his previous trade regime. Whether the UK's carefully negotiated carve-outs for steel, automotive, and pharmaceutical exports still apply is anyone's guess. For exporters shipping goods to their largest single-country market, the question isn't just about the additional cost—it's about the vacuum of clarity.

The whiplash is remarkable even by this administration's standards. Friday brought the Supreme Court's constitutional rejection of Trump's April "reciprocal tariffs" imposed under emergency powers. Friday night delivered a replacement executive order setting a 10% global rate. Saturday afternoon? That baseline jumped to 15%, declared "effective immediately" via Truth Social.

For UK exporters shipping goods to their largest single-country market—worth approximately £188bn in 2023 according to trade figures—the question isn't just about the additional cost. It's about the vacuum of clarity. UK officials are "understood to believe" that existing preferential arrangements will hold, but that's diplomatic language for hope rather than confirmation.

The exemption muddle

Here's where the confusion bites hardest. Under the short-lived 10% framework, Sir Keir Starmer's government secured what it termed an "Economic Prosperity Deal" with specific sector exemptions. British steel producers, car manufacturers, and pharmaceutical companies received carve-outs from the baseline rate—a material win for three export-heavy industries.

Whether those carve-outs survived Saturday's overnight revision remains unclear. The legal architecture underpinning Friday's deal may have been built on the 10% foundation. If that foundation has now shifted to 15%, does the exclusion structure remain intact, or does it need renegotiation?

We had feared that the President's plan B response could be worse for British businesses and so it is proving.

William Bain, head of trade policy at the British Chambers of Commerce, didn't mince words. "We had feared that the President's plan B response could be worse for British businesses and so it is proving," he said in a statement released Saturday. His organisation warned that the additional 5 percentage point increase would weaken global economic growth and deliver a blow to exporters already navigating post-Brexit trade friction.

What's interesting here is the asymmetry of information. The UK Government maintains publicly that it expects Britain's "privileged trading position" to continue. But expectation isn't the same as confirmation, and tariff policy executed via social media post doesn't lend itself to diplomatic back-channels operating on weekend schedules.

Implementation questions

Trump's declaration that the increase takes effect "immediately" raises practical questions for customs enforcement on both sides of the Atlantic. Tariff implementation typically requires notice periods for businesses to adjust documentation, pricing, and supply chain arrangements. Goods already in transit, letters of credit already drawn, and contracts already signed now exist in regulatory limbo.

British exporters shipping containerised goods this week face a calculation problem: invoice at existing prices and absorb potential 15% duties, or renegotiate terms with US buyers who may push back on mid-transit price changes? For sectors operating on thin margins—automotive components, for instance—a 15% duty isn't an inconvenience. It's a restructuring of the entire export proposition.

The pharmaceutical sector presents another wrinkle. UK life sciences companies exported £6.9bn worth of medicinal and pharmaceutical products to the US in 2023, according to ONS trade data. If the negotiated exemption holds, those flows continue largely unaffected. If it doesn't, patients and healthcare providers on the American side absorb higher costs whilst UK manufacturers weigh whether maintaining US market access justifies compressed margins.

Steel and automotive face similar stakes. Britain's steel industry, already operating under pressure from energy costs and global overcapacity, secured Friday's exemption as a lifeline. Tata Steel's Port Talbot operation and British Steel's Scunthorpe facility both maintain significant export exposure to US markets. A 15% tariff would effectively price many British steel grades out of American buyers' consideration.

What exporters should watch

The coming days will determine whether this is a technical adjustment within an existing framework or a wholesale reset requiring fresh negotiations. UK businesses should monitor three things: formal guidance from HMRC and the Department for Business and Trade on whether sector exemptions remain valid; US Customs and Border Protection implementation notices clarifying which goods face the higher rate; and any public statements from US Trade Representative Jamieson Greer's office addressing the status of bilateral arrangements.

For firms with imminent shipments, the prudent path involves scenario planning for both outcomes. That means modelling P&L impact at 15% across product lines, stress-testing customer relationships if price increases become necessary, and identifying which SKUs become commercially unviable at the higher duty rate.

After spending years negotiating Brexit on the promise of sovereign trade policy and global Britain, British exporters now find themselves more vulnerable to unilateral tariff adjustments from a single trading partner than they were as EU members benefiting from bloc-level negotiating weight.

The irony of the UK's position shouldn't be lost. After spending years negotiating Brexit on the promise of sovereign trade policy and global Britain, British exporters now find themselves more vulnerable to unilateral tariff adjustments from a single trading partner than they were as EU members benefiting from bloc-level negotiating weight.

Whether Whitehall's confidence that preferential treatment will continue proves justified depends entirely on decisions made in Washington, not London. For exporters planning Monday morning shipments, that realisation offers cold comfort.